AI and Robotics Drive 6.1% CAGR in the Acute Ischemic Stroke Diagnosis and Treatment Market

Allied Market Research published a report, titled, “Acute Ischemic Stroke Diagnosis and Treatment Market by Type (Diagnostics and Treatment), and End User, (Hospitals and Clinics, Ambulatory Surgery Centers, Diagnostic Laboratories and Imaging Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032″. The growth of the acute ischemic stroke diagnosis and treatment market is driven by a rise in incidences of acute ischemic stroke around the globe and technological advancements in ischemic stroke diagnostics. The global acute ischemic stroke diagnosis and treatment market size was valued at $5.1 billion in 2022, and is projected to reach $9.2 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032.

Acute Ischemic Stroke Diagnosis and Treatment Market in Short:

CAGR: 6.1%
Current Market Size: USD 9.2 Billion
Fastest Growing Region: APAC
Largest Market: North America
Projection Time: 2023-2032
Base Year: 2023

Request Downloadable Sample Copy of Report:
https://www.alliedmarketresearch.com/request-sample/1440

What is acute ischemic stroke?

Acute ischemic stroke refers to a sudden blockage of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This medical emergency can result in severe neurological deficits and complications.

What factors drive the growth of acute ischemic stroke diagnosis and treatment market?

The growth of the acute ischemic stroke diagnosis and treatment market is primarily driven by increasing awareness, early intervention initiatives, and advancements in diagnostic technologies, fostering timely and effective stroke management.

Value Propositions Related to The Report:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

Enquire Your Every Doubt Here:
https://www.alliedmarketresearch.com/purchase-enquiry/1440

Based on type, the treatment segment held the largest market share in 2022, accounting for more than three-fifths of the global acute ischemic stroke diagnosis and treatment market revenue. This segment is projected to attain the highest CAGR of 6.4% from 2023 to 2032. This is attributed to the increasing adoption of sophisticated treatment modalities, the notable success of mechanical thrombectomy, and continuous advancements in treatment methodologies have significantly enhanced the effectiveness of these advanced approaches.

Based on end user, the hospitals & clinics segment accounted for the largest market share in 2022, contributing to less than half of the global acute ischemic stroke diagnosis and treatment market revenue. This is attributed to healthcare facilities equipped with specialized resources, medical expertise, and comprehensive infrastructure essential for effective diagnosis and treatment of acute ischemic stroke cases.

Top Leading Key Companies –

• AstraZeneca plc
• Hoffmann-La Roche Ltd.
• Boehringer Ingelheim International GmbH
• GE Healthcare
• Koninklijke Philips N.V.
• Siemens
• Stryker Corporation
• Johnson & Johnson
• Medtronic plc
• Abbott Laboratories

Market: By Region Outlook

• North America (U.S., Canada, Mexico)
• Europe (UK, Germany, France, Spain, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
• LAMEA (Brazil, South Africa, Turkey, Saudi Arabia, Rest of LAMEA)

Procure Complete Report @
https://www.alliedmarketresearch.com/acute-ischemic-stroke-diagnosis-and-treatment-market/purchase-options

Important Questions Being Answered by This Market Report Are –

Q1. What is the total market value of acute ischemic stroke diagnosis and treatment market report?

Q2. What is the market value of acute ischemic stroke diagnosis and treatment market in 2032?

Q3. Which is base year calculated in the acute ischemic stroke diagnosis and treatment market report?

Q4. What would be forecast period in the market report?

Key findings of the study –

• In July 2022, Siemens Healthineers announced the Food and Drug Administration (FDA) clearance of the MAGNETOM Free.Star, a cost-effective whole-body magnetic resonance (MR) scanner designed to help improve patient access to MRI.
• In May 2023, Siemens Healthineers and CommonSpirit Health have agreed to acquire Block Imaging. This new acquisition will provide more sustainable options and support increasing demand from U.S. hospitals, health systems, and other care sites for multi-vendor imaging parts and services.
• In October 2023, Koninklijke Philips N.V., a global leader in health technology, and the World Stroke Organization (WSO), the world’s only global non-governmental organization focused on stroke, announced the signing of a two-year partnership aimed at improving access to high-quality stroke care.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com